Kinase Inhibitors

Targeting Cancer with Small Molecular Weight Kinase Inhibitors.- Small Molecule Protein and Lipid Kinase Inhibitors in Inflammation and Specific Models for their Evaluation.- Measuring the Activity of Leucine Rich Repeat Kinase 2 (LRRK2) – A Kinase Involved in Parkinson’s Disease.- Measuring PI3K Lipid Kinase Activity.- A Fluorescence Polarization Assay for the Discovery of Inhibitors of the Polo-box Domain of Polo-like Kinase 1.- Assessment of Hepatotoxicity Potential of Drug Candidate Molecules Including Kinase Inhibitors by Hepatocyte Imaging Assay Technology and Bile Flux Imaging Assay Technology.- Kinase Inhibitor Selectivity Profiling using Differential Scanning Fluorimetry.- Chemoproteomic Characterization of Protein Kinase Inhibitors using Immobilized ATP.- Proteome-wide identification of staurosporine-binding kinases using Capture Compound Mass Spectrometry.- Affinity Purification of Proteins Binding to Kinase Inhibitors Immobilised on Self Assembling Monolayers.- Kinase Inhibitor Profiling using Chemoproteomics.- Covalent Crosslinking of Kinases with Their Corresponding Peptide Substrates.- Receptor Tyrosine Kinase Inhibitor Profiling using Bead-based Multiplex Sandwich Immunoassays.- Monitoring PhosphoproteomicResponse To Targeted Kinase Inhibitors Using Reverse-Phase Protein Microarrays.- Measuring Phosphorylation Specific Changes in Response to Kinase Inhibitors in Mammalian Cells Using Quantitative Proteomics.- Investigation of Acquired Resistance to EGFR-Targeted Therapies in Lung Cancer Using cDNA Microarrays.